Ethiologic treatment of acute and chronic Chagas' Disease [corrected]
- PMID: 8650489
- DOI: 10.1590/s1516-31801995000200020
Ethiologic treatment of acute and chronic Chagas' Disease [corrected]
Erratum in
- Rev Paul Med 1995 Sep-Oct;113(5):1003
Abstract
The uncertainties in the ethiological treatment of Chagas' Disease are consequence of the lack of entire knowledge of its pathogeny and the no existence of a healing criterium. There is a consensus that antiparasite drugs should be in the acute phase of the infection, regardless of the infection route, in new crisis, in patients under immunosuppression and in organs transplantation. There is still controversy regarding subacute, chronic or indetermined phase or cases with mild cardia/digestive forms, not included in the situations listed above neither in a research protocol. The treatment includes oral benzonidazol 5 mg/kg/dat, bid or tid for 60 days. In 71 patients monitored in this fashion, the authors have found 60% of negative xenodiagnostic at the end of treatment It is still necessary, however, to continue to investigate and accomplishing more randomized trials to confirm the efficacy of such method, and also to try to obtain effective and less toxic agents. It is also fundamental to standardize a more reliable healing criterium.
Similar articles
-
Benznidazole for Chronic Chagas' Cardiomyopathy.N Engl J Med. 2016 Jan 14;374(2):189. doi: 10.1056/NEJMc1514453. N Engl J Med. 2016. PMID: 26760095 No abstract available.
-
Benznidazole for Chronic Chagas' Cardiomyopathy.N Engl J Med. 2016 Jan 14;374(2):188-9. doi: 10.1056/NEJMc1514453. N Engl J Med. 2016. PMID: 26760094 No abstract available.
-
Benznidazole for Chronic Chagas' Cardiomyopathy.N Engl J Med. 2016 Jan 14;374(2):188. doi: 10.1056/NEJMc1514453. N Engl J Med. 2016. PMID: 26760093 No abstract available.
-
Antitrypanosomal therapy for chronic Chagas' disease.N Engl J Med. 2011 Jun 30;364(26):2527-34. doi: 10.1056/NEJMct1014204. N Engl J Med. 2011. PMID: 21714649 Review. No abstract available.
-
Chagas disease: Present status of pathogenic mechanisms and chemotherapy.Biol Res. 2010;43(3):323-31. Epub 2010 Nov 30. Biol Res. 2010. PMID: 21249304 Review.
Cited by
-
Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.Open Med Chem J. 2011;5:21-30. doi: 10.2174/1874104501105010021. Epub 2011 Mar 9. Open Med Chem J. 2011. PMID: 21629508 Free PMC article.
-
Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.Clin Diagn Lab Immunol. 2003 Sep;10(5):826-30. doi: 10.1128/cdli.10.5.826-830.2003. Clin Diagn Lab Immunol. 2003. PMID: 12965912 Free PMC article.
-
A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.Mem Inst Oswaldo Cruz. 2013 Nov;108(7):873-80. doi: 10.1590/0074-0276130122. Mem Inst Oswaldo Cruz. 2013. PMID: 24037109 Free PMC article.
-
Immunopathological aspects of experimental Trypanosoma cruzi reinfections.Biomed Res Int. 2014;2014:648715. doi: 10.1155/2014/648715. Epub 2014 Jun 24. Biomed Res Int. 2014. PMID: 25050370 Free PMC article.
-
Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil.Trop Med Infect Dis. 2020 Aug 18;5(3):132. doi: 10.3390/tropicalmed5030132. Trop Med Infect Dis. 2020. PMID: 32824760 Free PMC article.